Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Cash & Equivalents (2020 - 2025)

NeuroPace (NPCE) has 6 years of Cash & Equivalents data on record, last reported at $21.7 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 61.52% year-over-year to $21.7 million; the TTM value through Dec 2025 reached $21.7 million, up 61.52%, while the annual FY2025 figure was $21.7 million, 61.52% up from the prior year.
  • Cash & Equivalents reached $21.7 million in Q4 2025 per NPCE's latest filing, up from $20.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $31.2 million in Q2 2021 and bottomed at $5.7 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $15.1 million, with a median of $13.4 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 212.5% in 2021, then tumbled 81.75% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $26.6 million in 2021, then tumbled by 78.64% to $5.7 million in 2022, then surged by 217.48% to $18.1 million in 2023, then dropped by 25.63% to $13.4 million in 2024, then soared by 61.52% to $21.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $21.7 million in Q4 2025, $20.6 million in Q3 2025, and $27.0 million in Q1 2025.